ClinicalTrials.gg
CompletedNCT02777554Updated Jul 22, 2021Results posted

A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults

A Phase 1 interventional study of Apremilast IR and Apremilast XL in Healthy Volunteers, sponsored by Amgen. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-22.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the relative bioavailability of apremilast once-daily formulation relative to a twice daily formulation when administered as multiple doses (Part 1), and when administered as a single dose under fasting and fed conditions (Part 2). Information on safety and tolerability will also be obtained.

Read the detailed description

Part 1: This is an open-label, randomized, two-period, two-sequence, crossover study in healthy subjects. The study will consist of a screening phase, a baseline phase, two treatment periods, and a follow-up phone call. Each period will be ten days in duration including 7 days of dosing and sample collection for up to 72 hours post Day 7 morning dose. There will be a washout between period 1 and period 2.

Part 2: This is an open-label, randomized, four-period, four-sequence crossover study to evaluate the PK and exposure of apremilast following single dose administration of different formulations of apremilast. Part 2 will consist of a screening phase, baseline, four treatment periods, and a follow-up phone call. Each period will be four days in duration for dosing (Day 1) and sample collection for up to 72 hours post Day 1.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Subjects
  • Apremilast
  • Pharmacokinetic
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study (Part 1 and Part 2):

  1. Must understand and voluntarily sign a written form (ICF) prior to any study-related procedures being performed.
  2. Must be able to communicate with the investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules.
  3. Male and female subjects of any race between 18 to 55 years of age (inclusive), and in good health as determined by the Investigator at the time of signing the informed consent document.
  4. Have a (BMI) between 18 and 33 kg/m\^2 (inclusive).
  5. No laboratory test results as determined by the investigator.
  6. At the screening visit, must be afebrile, with supine systolic blood pressure (BP): 90 to 140 mmHg, supine diastolic BP: 50 to 90 mmHg, and pulse rate: 40 to 110 bpm. Eligibility criteria for vital signs performed during check-in and/or predose on Day 1 will be at the discretion of the Investigator.
  7. Must have a normal or clinically acceptable 12-lead (ECG). Subjects must have a corrected using the Fridericia formula (QTcF) value ≤ 450 msec.
  8. Female subjects

    1. Must have a negative pregnancy test
    2. If : must have follicular stimulating hormone (FSH) test result > 40 IU/L and a negative pregnancy test
  9. Requirements:

    Must comply with the following acceptable forms of contraception. All Female of child bearing potential (FCBP)1 must use one of the approved contraceptive options as described below while taking apremilast and for at least 28 days after administration of the last dose of the apremilast. At the time of study entry, and at any time during the study when a FCBP's contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy.

    All FCBP must have a negative pregnancy test at Screening and Day -1 of each Treatment Period. All FCBP subjects who engage in activity in which conception is possible must use one of the approved contraceptive options described below:

    Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural [animal] membrane [for example, polyurethane]); Plus one additional barrier(c) contraceptive sponge with spermicide.

    Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex or non-latex condoms NOT made out of natural [animal] membrane [for example, polyurethane]) while on Product (IP) and for at least 28 days after the last dose of IP.

  10. Must agree to refrain from donating sperm, blood or plasma (other than for this study) while participating in this study and for at least 28 days after the last dose of investigational product.
  11. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. History of any and relevant neurological, psychiatric, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders.
  2. Any condition which places the subject at unacceptable risk if he were to participate in the study, or confounds the ability to interpret data from the study.

1 A female of is a sexually mature female who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been for at least 24 consecutive months (that is, has had menses at any time during the preceding 24 consecutive months).

  1. Use of any prescribed systemic or topical medication within 30 days of the first dose administration (exception, FCBP may use hormonal ).
  1. Use of any non-prescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of the first dose administration.
  1. Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism and excretion, eg, bariatric procedure, colon resection, irritable bowel syndrome, Crohn's disease, etc. Subjects with cholecystectomy and appendectomy may be included.
  1. Exposure to an drug (new chemical entity) within 30 days prior to the first dose administration or 5 half-lives of that investigational drug, if known (whichever is longer).
  1. Donated blood or plasma within 8 weeks before the first dose administration to a blood bank or blood donation center.
  1. History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual [DSM]) within 2 years before dosing, or a positive drug screen reflecting consumption of illicit drugs.
  1. History of alcohol abuse (as defined by the current version of the DSM) within 2 years before dosing, or a positive alcohol screen.
  1. Known to have hepatitis, or known to be a carrier of the surface antigen (HBsAg) or antibody (HCV Ab), or have a positive result to the test for (HIV) antibodies at screening.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Part 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QD

    Participants received apremilast 30 mg immediate release (IR) tablet twice a day (BID) for 7 days in treatment period 1 then apremilast 75 mg extended release (XL) formulation once a day (QD) for 7 days in treatment period 2.

    Drug: Apremilast IR · Drug: Apremilast XL

  • Experimental
    Part 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BID

    Participants received apremilast 75 mg XL formulation once a day for 7 days in treatment period 1 then apremilast 30 mg IR tablet twice a day for 7 days in treatment period 2.

    Drug: Apremilast IR · Drug: Apremilast XL

  • Experimental
    Part 2: Sequence 1

    Participants received a single dose of apremilast in each of 4 treatment periods according to the following: Treatment period 1: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 2: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 3: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation after a standard meal.

    Drug: Apremilast IR · Drug: Apremilast XL

  • Experimental
    Part 2: Sequence 2

    Participants received a single dose of apremilast in each of 4 treatment periods according to the following: Treatment period 1: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 2: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a standard meal; Treatment period 4: Apremilast 75 mg XL formulation after a high-fat meal.

    Drug: Apremilast IR · Drug: Apremilast XL

  • Experimental
    Part 2: Sequence 3

    Participants received a single dose of apremilast in each of 4 treatment periods according to the following: Treatment period 1: Apremilast 75 mg XL formulation after a standard meal; Treatment period 2: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 4: Apremilast 30 mg IR tablet under fasted conditions.

    Drug: Apremilast IR · Drug: Apremilast XL

  • Experimental
    Part 2: Sequence 4

    Participants received a single dose of apremilast in each of 4 treatment periods according to the following: Treatment period 1: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 2: Apremilast 75 mg XL formulation after a standard meal; Treatment period 3: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation under fasted conditions.

    Drug: Apremilast IR · Drug: Apremilast XL

Interventions

  • Apremilast immediate release tablet

    Also known as: Otezla®

  • DrugApremilast XL

    Apremilast extended release formulation tablet

06

What researchers measure

Primary outcomes

  1. Part 1: Peak Maximum Plasma Concentration (Cmax) of Apremilast

    Time frame: Apremilast IR: Day 7 predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, and 24 hours after the morning dose. Apremilast XL: Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours after the morning dose.

  2. Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Apremilast

    Time frame: Apremilast IR: Day 7 predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, and 24 hours after the morning dose. Apremilast XL: Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours after the morning dose.

  3. Part 2: Peak Maximum Plasma Concentration (Cmax) of Apremilast

    Time frame: Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.

  4. Part 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Observable Concentration (AUC0-t) of Apremilast

    Time frame: Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.

  5. Part 2: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast

    Time frame: Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events

    An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. A serious AE is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator determined the relationship between the administration of study drug and the occurrence of each AE as Not Suspected or Suspected as defined in the Protocol.

    Time frame: Part 1: Up to 7 days after last dose in each treatment period (14 days); Part 2: Up to 7 days after each dose.

07

Results

Posted Jul 22, 2021

Participant flow

This study was conducted at 2 clinical sites in the United States. The study consisted of 2 parts. Part 1 was a multiple-dose two-period, two-sequence, crossover study. Part 2 was a four-period, four-sequence crossover study. Both parts enrolled healthy volunteers.

Participant flow — Overall Study
MilestonePart 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QDPart 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BIDPart 2: Sequence 1Part 2: Sequence 2Part 2: Sequence 3Part 2: Sequence 4
Started62625555
Completed32374455
Not completed30251100
Withdrew: Adverse event440100
Withdrew: Withdrawal by subject311000
Withdrew: Discharged early due to hurricane22200000
Withdrew: Other - miscellaneous100000

Outcome measures

PrimaryPart 1: Peak Maximum Plasma Concentration (Cmax) of Apremilast
Time frame:
Apremilast IR: Day 7 predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, and 24 hours after the morning dose. Apremilast XL: Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours after the morning dose.
Reported as:
Geometric mean · ng/mL
Part 1: Peak Maximum Plasma Concentration (Cmax) of Apremilast
ng/mLPart 1: Apremilast 30 mg IR BIDPart 1: Apremilast 75 mg XL QD
Part 1: Peak Maximum Plasma Concentration (Cmax) of Apremilast451 ± 49.0459 ± 35.0
Statistical analysis
  • Part 1: Apremilast 30 mg IR BID vs Part 1: Apremilast 75 mg XL QD · Ratio (%) of geometric means: 101.6 · 90% CI 95.1 to 108.5Geometric mean ratio (Apremilast 75 mg XL QD / Apremilast 30 mg IR BID) from an ANOVA model, expressed as a percentage.
PrimaryPart 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Apremilast
Time frame:
Apremilast IR: Day 7 predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, and 24 hours after the morning dose. Apremilast XL: Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours after the morning dose.
Reported as:
Geometric mean · ng*hr/mL
Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Apremilast
ng*hr/mLPart 1: Apremilast 30 mg IR BIDPart 1: Apremilast 75 mg XL QD
Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Apremilast6370 ± 51.26090 ± 46.1
Statistical analysis
  • Part 1: Apremilast 30 mg IR BID vs Part 1: Apremilast 75 mg XL QD · Ratio (%) of geometric means: 95.3 · 90% CI 88.9 to 102.2Geometric mean ratio (Apremilast 75 mg XL QD / Apremilast 30 mg IR BID) from an ANOVA model, expressed as a percentage.
PrimaryPart 2: Peak Maximum Plasma Concentration (Cmax) of Apremilast
Time frame:
Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.
Reported as:
Geometric mean · ng/mL
Part 2: Peak Maximum Plasma Concentration (Cmax) of Apremilast
ng/mLPart 2: Apremilast 30 mg IR BID (Fasted)Part 2: Apremilast 75 mg XL (Fasted)Part 2: Apremilast 75 mg XL (Standard Meal)Part 2: Apremilast 75 mg XL (High Fat Meal)
Part 2: Peak Maximum Plasma Concentration (Cmax) of Apremilast379 ± 29.9402 ± 32.5436 ± 33.2496 ± 25.2
Statistical analysis
  • Part 2: Apremilast 30 mg IR BID (Fasted) vs Part 2: Apremilast 75 mg XL (Fasted) · Ratio (%) of geometric means: 103.9 · 90% CI 93.6 to 115.4Geometric mean ratio (Apremilast 75 mg XL / Apremilast 30 mg IR BID) from an ANOVA model, expressed as a percentage.
  • Part 2: Apremilast 75 mg XL (Fasted) vs Part 2: Apremilast 75 mg XL (Standard Meal) · Ratio (%) of geometric means: 90.9 · 90% CI 81.6 to 101.3Geometric mean ratio (Apremilast 75 mg XL (Fasted) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.
  • Part 2: Apremilast 75 mg XL (Standard Meal) vs Part 2: Apremilast 75 mg XL (High Fat Meal) · Ratio (%) of geometric means: 115.0 · 90% CI 103.3 to 128.1Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.
  • Part 2: Apremilast 75 mg XL (Fasted) vs Part 2: Apremilast 75 mg XL (High Fat Meal) · Ratio (%) of geometric means: 126.5 · 90% CI 113.7 to 140.8Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Fasted)) from an ANOVA model, expressed as a percentage.
PrimaryPart 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Observable Concentration (AUC0-t) of Apremilast
Time frame:
Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.
Reported as:
Geometric mean · ng*h/mL
Part 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Observable Concentration (AUC0-t) of Apremilast
ng*h/mLPart 2: Apremilast 30 mg IR BID (Fasted)Part 2: Apremilast 75 mg XL (Fasted)Part 2: Apremilast 75 mg XL (Standard Meal)Part 2: Apremilast 75 mg XL (High Fat Meal)
Part 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Observable Concentration (AUC0-t) of Apremilast7030 ± 31.56650 ± 42.57580 ± 31.17400 ± 31.1
Statistical analysis
  • Part 2: Apremilast 30 mg IR BID (Fasted) vs Part 2: Apremilast 75 mg XL (Fasted) · Ratio (%) of geometric means: 92.9 · 90% CI 81.3 to 106.2Geometric mean ratio (Apremilast 75 mg XL / Apremilast 30 mg IR BID) from an ANOVA model, expressed as a percentage.
  • Part 2: Apremilast 75 mg XL (Fasted) vs Part 2: Apremilast 75 mg XL (Standard Meal) · Ratio (%) of geometric means: 86.0 · 90% CI 74.9 to 98.7Geometric mean ratio (Apremilast 75 mg XL (Fasted) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.
  • Part 2: Apremilast 75 mg XL (Standard Meal) vs Part 2: Apremilast 75 mg XL (High Fat Meal) · Ratio (%) of geometric means: 97.3 · 90% CI 84.9 to 111.6Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.
  • Part 2: Apremilast 75 mg XL (Fasted) vs Part 2: Apremilast 75 mg XL (High Fat Meal) · Ratio (%) of geometric means: 113.2 · 90% CI 98.8 to 129.7Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Fasted)) from an ANOVA model, expressed as a percentage.
PrimaryPart 2: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast
Time frame:
Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.
Reported as:
Geometric mean · ng*h/mL
Part 2: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast
ng*h/mLPart 2: Apremilast 30 mg IR BID (Fasted)Part 2: Apremilast 75 mg XL (Fasted)Part 2: Apremilast 75 mg XL (Standard Meal)Part 2: Apremilast 75 mg XL (High Fat Meal)
Part 2: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast7100 ± 31.46680 ± 42.47600 ± 31.17450 ± 31.1
Statistical analysis
  • Part 2: Apremilast 30 mg IR BID (Fasted) vs Part 2: Apremilast 75 mg XL (Fasted) · Ratio (%) of geometric means: 92.6 · 90% CI 81.1 to 105.9Geometric mean ratio (Apremilast 75 mg XL / Apremilast 30 mg IR BID) from an ANOVA model, expressed as a percentage.
  • Part 2: Apremilast 75 mg XL (Fasted) vs Part 2: Apremilast 75 mg XL (Standard Meal) · Ratio (%) of geometric means: 86.1 · 90% CI 75.0 to 98.8Geometric mean ratio (Apremilast 75 mg XL (Fasted) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.
  • Part 2: Apremilast 75 mg XL (Standard Meal) vs Part 2: Apremilast 75 mg XL (High Fat Meal) · Ratio (%) of geometric means: 97.5 · 90% CI 85.0 to 111.8Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.
  • Part 2: Apremilast 75 mg XL (Fasted) vs Part 2: Apremilast 75 mg XL (High Fat Meal) · Ratio (%) of geometric means: 113.2 · 90% CI 98.8 to 129.7Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Fasted)) from an ANOVA model, expressed as a percentage.
SecondaryNumber of Participants With Treatment-emergent Adverse Events

An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. A serious AE is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator determined the relationship between the administration of study drug and the occurrence of each AE as Not Suspected or Suspected as defined in the Protocol.

Time frame:
Part 1: Up to 7 days after last dose in each treatment period (14 days); Part 2: Up to 7 days after each dose.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsPart 1: Apremilast 30 mg IR BIDPart 1: Apremilast 75 mg XL QDPart 2: Apremilast 30 mg IR BID (Fasted)Part 2: Apremilast 75 mg XL (Fasted)Part 2: Apremilast 75 mg XL (Standard Meal)Part 2: Apremilast 75 mg XL (High Fat Meal)
Any treatment-emergent adverse event (TEAE)50472432
TEAE related to study drug45412322
Serious adverse events000000
Serious adverse events related to study drug000000
TEAE leading to discontinuation351000
TEAE related to study drug leading to discontinuation351000
Deaths000000

Adverse events

Collected over Part 1: Up to 7 days after last dose in each treatment period (14 days); Part 2: Up to 7 days after each dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Apremilast 30 mg IR BID—0/108 (0%)41/108 (38%)
Part 1: Apremilast 75 mg XL QD—0/107 (0%)35/107 (32.7%)
Part 1 Total—0/124 (0%)59/124 (47.6%)
Part 2: Apremilast 30 mg IR (Fasted)—0/20 (0%)2/20 (10%)
Part 2: Apremilast 75 mg XL (Fasted)—0/19 (0%)4/19 (21.1%)
Part 2: Apremilast 75 mg XL (Standard Meal)—0/18 (0%)3/18 (16.7%)
Part 2: Apremilast 75 mg XL (High Fat Meal)—0/19 (0%)2/19 (10.5%)
Part 2 Total—0/20 (0%)8/20 (40%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPart 1: Apremilast 30 mg IR BIDPart 1: Apremilast 75 mg XL QDPart 1 TotalPart 2: Apremilast 30 mg IR (Fasted)Part 2: Apremilast 75 mg XL (Fasted)Part 2: Apremilast 75 mg XL (Standard Meal)Part 2: Apremilast 75 mg XL (High Fat Meal)Part 2 Total
HeadacheNervous system disorders27/10825/10743/1240/201/192/182/195/20
DiarrhoeaGastrointestinal disorders15/10813/10721/1241/202/190/180/192/20
NauseaGastrointestinal disorders11/1087/10716/1241/201/190/182/193/20
MyalgiaMusculoskeletal and connective tissue disorders8/1088/10715/1240/200/190/180/190/20
VomitingGastrointestinal disorders2/1083/1075/1241/200/190/181/192/20
DizzinessNervous system disorders2/1082/1074/1241/201/190/180/192/20
ArthralgiaMusculoskeletal and connective tissue disorders2/1087/1078/1240/200/190/180/190/20
Muscle spasmsMusculoskeletal and connective tissue disorders6/1083/1078/1240/200/190/180/190/20
FatigueGeneral disorders5/1085/1077/1240/200/190/180/190/20
DyspepsiaGastrointestinal disorders3/1080/1073/1241/200/191/180/191/20

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)Part 1Part 2Total
Mean37.8 (19 to 55)34.7 (20 to 53)37.4 (19 to 55)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1Part 2Total
Female46753
Male781391
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1Part 2Total
Hispanic or Latino52860
Not Hispanic or Latino721284
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1Part 2Total
American Indian or Alaska Native101
Black or African American471057
White701080
Asian404
Other202
08

Study locations

2 sites
  • Covance-Daytona Beach
    Daytona Beach, Florida 32117, United States
  • Covance Clinical Research Unit Inc
    Madison, Wisconsin 53704, United States
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Nov 2016, 3 months.

Results were first posted in Jul 2021, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2016
First posted
May 19, 2016
StartActual
Aug 17, 2016
Primary completionActual
Nov 22, 2016
CompletionActual
Nov 22, 2016
Results first posted
Jul 22, 2021
Last update
Jul 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02777554
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 19, 2016
Start date
Aug 17, 2016
Primary completion
Nov 22, 2016
Completion
Nov 22, 2016
Results posted
Jul 22, 2021
Last update
Jul 22, 2021

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion